Efficacy and safety of nintedanib 1 docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO

被引：0
|
作者：
Grohe, C. [1 ]
Gleiber, W. [2 ]
Haas, S. [3 ,4 ]
Krueger, S. [5 ]
Schulze, M. [6 ]
Atz, J. [7 ]
Kaiser, R. [7 ]
机构：
[1] ELK Berlin, Dept Pneumol, Berlin, Germany
[2] Univ Hosp Frankfurt, Pneumol Allergol, Frankfurt, Germany
[3] FEK, Clin Haematol, Neumunster, Germany
[4] FEK, Clin Oncol & Nephrol, Neumunster, Germany
[5] Florence Nightingale Hosp, Dept Pulmonol Allergol Sleep Med & Resp Care, Dusseldorf, Germany
[6] Ambulante Onkol Ostsachsen, Zittau, Germany
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Med Affairs Oncol, Ingelheim, Germany
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1505P
引用
收藏
页码：618 / 618
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First results of the ongoing non-interventional study (NIS) VARGADO
    Grohe, C.
    Gleiber, W.
    Haas, S.
    Mueller-Huesmann, H.
    Schulze, M.
    Atz, J.
    Kaiser, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] Efficacy and safety of nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
    Grohe, C.
    Gleiber, W.
    Krueger, S.
    Mueller-Huesmann, H.
    Schulze, M.
    Atz, J.
    Kaiser, R.
    ANNALS OF ONCOLOGY, 2019, 30 : 24 - 24
  • [3] Efficacy and safety of nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
    Grohe, C.
    Blau, W.
    Gleiber, W.
    Haas, S.
    Krueger, S.
    Schulze, M.
    Atz, J.
    Kaiser, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 132 - 132
  • [4] Nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated efficacy and safety results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455).
    Grohe, Christian
    Blau, Wolfgang
    Gleiber, Wolfgang
    Haas, Siegfried
    Krueger, Stefan
    Mueller-Huesmann, Harald
    Schulze, Mathias
    Atz, Judith
    Kaiser, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Preliminary efficacy and safety results of the non-interventional study VARGADO.
    Grohe, Christian
    Blau, Wolfgang
    Gleiber, Wolfgang
    Haas, Siegfried
    Mueller-Huesmann, Harald
    Schulze, Mathias
    Atz, Judith
    Kaiser, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Efficacy and safety of nintedanib and docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First interim results of the ongoing non-interventional study VARGADO (NCT02392455)
    Grohe, C.
    Gleiber, W.
    Haas, S.
    Mueller-Huesmann, H.
    Schulze, M.
    Atz, J.
    Kaiser, R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Efficacy and safety of nintedanib plus docetaxel in lung adenocarcinoma patients (pts) after failure of previous immune checkpoint inhibitor therapy (ICIs): Updated results from the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
    Grohe, C.
    Gleiber, W.
    Haas, S.
    Hammerschmidt, S.
    Krueger, S.
    Mueller-Huesmann, H.
    Schulze, M.
    Wehler, T.
    Atz, J.
    Kaiser, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S875 - S876
  • [8] Efficacy and safety of nintedanib plus docetaxel in lung adenocarcinoma patients (pts) after failure of previous immune checkpoint inhibitor therapy (ICIs): Updated results from the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
    Grohe, C.
    Hammerschmidt, S.
    Krueger, S.
    Mueller-Huesmann, H.
    Schulze, M.
    Wehler, T.
    Atz, J.
    Kaiser, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 136 - 137
  • [9] Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study
    Grohe, C.
    Blau, W.
    Gleiber, W.
    Haas, S.
    Hammerschmidt, S.
    Krueger, S.
    Mueller-Huesmann, H.
    Schulze, M.
    Wehler, T.
    Atz, J.
    Kaiser, R.
    CLINICAL ONCOLOGY, 2022, 34 (07) : 459 - 468
  • [10] Impact of KRAS status on the efficacy of nintedanib plus docetaxel following treatment with first-line immune checkpoint inhibitor plus chemotherapy in patients with adenocarcinoma NSCLC: analysis of cohort C of the non-interventional VARGADO trial
    Grohe, C.
    Wehler, T.
    Henschke, S.
    Hammerschmidt, S.
    Aulmann, C.
    Krueger, S.
    Dittrich, I.
    Schuette, W.
    von der Heyde, E.
    Stammberger, A.
    Bajorat, J.
    Kaiser, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 229 - 229
12345